Recent discovery lowering 4601 dev cost
1)
Cancer Genonme Atlas is mapping out GBM cancer type.
They are now entering phase II - as another subset of genes will be mapped out for mutations and variances.
This project basically validates RAS-Mapk pathway and shows link to AKT, p53 and RS.
This is saving millions in research cost for TLN, as they can now better target their tests toward obtaining efficacity data.
2) KRAS has been in a fore front of cancer treatment.
No available drugs are capable of treating Mutated KRAS.
It's now a biomarker indicating certain death.
4601 is the most advanced anti-KRAS compound currently being tested.
Way back are compounds in early discovery and in PI.
Unknown Pharma buyer showed up right after both of these focus in cancer research surface in H2 2008.